What is SensaT.R.A.C.™ Technology?
The patented SensaT.R.A.C.™ Technology continuously monitors, measures and maintains the prescribed negative pressure at the wound site for optimal healing outcomes.

**Monitoring and Adjusting Software**
- Continuously monitors and maintains prescribed negative pressure at the wound site
- Adjusts pump output, compensating for wound distance, wound position, exudate characteristics, and patient movement
- Safety alarms alert caregivers if target pressure is not met or therapy is interrupted

**SensaT.R.A.C.™ Tubing**
- Efficiently draws exudate away from the wound through the large inner lumen
- Independently monitors target pressure at the wound through outer sensing lumens

**SensaT.R.A.C.™ Pad**
- Distributes negative pressure to individual sensing lumens
- Helps reduce tubing blockages and false alarms
- Enhances patient comfort with a low profile design
Why SensaT.R.A.C.™ Technology?

KCI V.A.C.® Negative Pressure Wound Therapy integrated with SensaT.R.A.C.™ Technology was shown in bench testing to perform significantly better in accurately delivering prescribed negative pressure at the simulated wound site and efficiently removing fluid from the simulated wound site.

Benchtop NPWT studies1-2 demonstrated the KCI ActiV.A.C.® Negative Pressure Wound Therapy Unit, with SensaT.R.A.C.™ Technology, delivered target negative pressure (-125mmHg) to the simulated wound site when the dressing was elevated 36 inches above the therapy unit and used to pull a column of simulated wound fluid. The Genadyne XLR8® Negative Pressure Wound Therapy Unit and the Medela Invia® Motion™ Negative Pressure Wound Therapy Unit showed a drop in pressure due to height difference from the simulated wound and removal of simulated wound fluid from the dressing (3 units/group x 3 runs/group).

**Accurately delivered prescribed negative pressure3,4**

Effect of Vertical Distance on Delivery of Negative Pressure

![Graph showing the mean difference from target pressure (mmHg) for different units at 0 and 36 inches](chart)

**Key Takeaway**

The XLR8® Therapy Units and the Invia® Motion™ Therapy Units were tested under similar conditions as ActiV.A.C.® Therapy Units. Mean pressure differential from target pressure at 36" vertical distance:

- ActiV.A.C.® Therapy Unit = 0.6mmHg
- XLR8® Therapy Unit = -18.3mmHg
- Invia® Motion™ Therapy Unit = -19.2mmHg

**Only KCI V.A.C.® Therapy Units provide patented SensaT.R.A.C.™ Technology, a real-time pressure feedback system that:**

- Adjusts pump output, compensating for wound distance, wound position, exudate characteristics, and patient movement
- Delivers and maintains prescribed negative pressure at the wound site

![Graph showing time to remove fluid from simulated wound site](chart)

**Time to remove fluid from simulated wound site5**

<table>
<thead>
<tr>
<th>Therapy Unit</th>
<th>Time to Remove 80mL of Simulated Exudate</th>
</tr>
</thead>
<tbody>
<tr>
<td>ActiV.A.C.® Therapy</td>
<td>¼ hour</td>
</tr>
<tr>
<td>XLR8® Therapy</td>
<td>24 hours</td>
</tr>
<tr>
<td>Invia® Motion™ Therapy</td>
<td>Did not achieve in 24 hours (removes 67mL in 24 hours)</td>
</tr>
</tbody>
</table>

**Are Your NPWT Patients on T.R.A.C.™?**

For more information, call 1.800.275.4524 or visit www.kci1.com

References:
1. KCI product bench study data on file, November 2013
2. KCI product bench study data on file, December 2013
3. V.A.C.® Therapy target pressure can vary +/- 10mmHg per IFU. Pressure set at -125mmHg for ActiV.A.C.® Therapy Unit, Genadyne XLR8® Therapy Unit and Medela Invia® Motion™ Therapy Unit
4. The fluid inflow rate used is 0.83mL/min of an albumin based simulated wound exudate
5. Containing 180mL of albumin based simulated wound exudate. Pressure set at -125mmHg for ActiV.A.C.® Therapy Unit, Genadyne XLR8® Therapy Unit and Medela Invia® Motion™ Therapy Unit

NOTE: Correlation of bench-top results in humans has not been established in specific clinical studies.

NOTE: Specific indications, contraindications, warnings, precautions and safety information exist for KCI products and therapies. Please consult a physician and product instructions for use prior to application. Rx only.

©2014 KCI Licensing, Inc. All rights reserved. XLR8 is a trademark of Genadyne. Invia Motion is a trademark of Medela. All other trademarks designated herein are proprietary to KCI Licensing, Inc., its affiliates and/or licensors. DSI#14-0461.US LIT#29-L-195 (REV. 12/14)